Arcticzymes Technologies ASA
OSE:AZT
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
12.74
40.55
|
| Price Target |
|
We'll email you a reminder when the closing price reaches NOK.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Arcticzymes Technologies ASA
Arcticzymes Technologies ASA
Revenue
Arcticzymes Technologies ASA
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
Revenue
kr108.2m
|
CAGR 3-Years
3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
14%
|
|
|
Hofseth Biocare ASA
OSE:HBC
|
Revenue
kr239.9m
|
CAGR 3-Years
42%
|
CAGR 5-Years
28%
|
CAGR 10-Years
20%
|
|
|
B
|
Bergenbio ASA
OSE:BGBIO
|
Revenue
kr521k
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
Revenue
kr4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
Revenue
$3.9m
|
CAGR 3-Years
-74%
|
CAGR 5-Years
279%
|
CAGR 10-Years
N/A
|
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
Revenue
kr0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Arcticzymes Technologies ASA
Glance View
ArcticZymes Technologies ASA is a holding company, which engages in the development, manufacture, and marketing of immunomodulatory products and cold adapted marine enzymes. The company is headquartered in Tromso, Troms. The company went IPO on 2005-11-04. The firm focuses on new solutions within molecular research, in vitro diagnostics and therapeutics. Arcticzymes Technologies ASA invests in BetaGlucans, which develops immunomodulating beta-glucan products, serving several different market segments including wound care, animal and consumer health and adjuvants.
See Also
What is Arcticzymes Technologies ASA's Revenue?
Revenue
108.2m
NOK
Based on the financial report for Sep 30, 2024, Arcticzymes Technologies ASA's Revenue amounts to 108.2m NOK.
What is Arcticzymes Technologies ASA's Revenue growth rate?
Revenue CAGR 10Y
14%
Over the last year, the Revenue growth was -9%. The average annual Revenue growth rates for Arcticzymes Technologies ASA have been 3% over the past three years , 8% over the past five years , and 14% over the past ten years .
You don't have any saved screeners yet